The long-term epigenetic effects of VPA are reported to modulate gene transcription and synaptic receptors and several signaling molecules, which are involved in excitotoxicity and neuroprotection [133]
Food and Drug Administration, nausea, vomiting, diarrhea, and constipation are frequently reported, particularly early in treatment
If all goes well, FDA-approval and release will likely not happen until 2026 or beyond
One area of focus is long-term studies that follow patients over several years
There is no confirmed brand-name option on Mochi at this time
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (interim category 2 list on which BPC-157 and related peptides were placed in 2023